Leerink Swann restated their market perform rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research note issued to investors on Friday. They currently have a $72.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $83.00. The analysts noted that the move was a valuation call.
Several other equities research analysts have also weighed in on ALNY. Chardan Capital reissued a buy rating and set a $124.00 target price (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Stifel Nicolaus reissued a buy rating and set a $56.00 target price (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. BMO Capital Markets reissued an outperform rating and set a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the stock an equal weight rating in a research report on Thursday, August 10th. Finally, Barclays PLC raised their target price on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an equal weight rating in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $83.50.
Alnylam Pharmaceuticals (ALNY) opened at 78.68 on Friday. The company’s market capitalization is $7.22 billion. The firm has a 50-day moving average of $81.97 and a 200-day moving average of $67.86. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $89.45.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative return on equity of 48.62% and a negative net margin of 743.28%. The business had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same period last year, the business posted ($1.05) EPS. Alnylam Pharmaceuticals’s revenue was up 82.9% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals will post ($5.18) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Leerink Swann” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/12/alnylam-pharmaceuticals-inc-alny-stock-rating-reaffirmed-by-leerink-swann.html.
Hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. grew its stake in shares of Alnylam Pharmaceuticals by 22.0% in the 2nd quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock valued at $926,000 after purchasing an additional 2,093 shares during the last quarter. TLP Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at approximately $380,000. Wellington Management Group LLP boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after buying an additional 31,208 shares in the last quarter. BB Biotech AG boosted its stake in shares of Alnylam Pharmaceuticals by 4.2% in the first quarter. BB Biotech AG now owns 1,241,338 shares of the biopharmaceutical company’s stock valued at $63,619,000 after buying an additional 50,000 shares in the last quarter. Finally, Hemenway Trust Co LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $235,000. Institutional investors own 94.27% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.